Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 24 March 2017, 07:00 HKT/SGT
Share:
    

Source: Nanobiotix
NANOBIOTIX: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma

Paris, France and Cambridge, Mass, USA, Mar 24, 2017 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that the Independent Data Monitoring Committee (IDMC) has completed the interim evaluation of the Phase II/III trial results (Act.In.Sarc) of NBTXR3 in soft tissue sarcoma.

The interim evaluation was based on an analysis of the results of two-thirds of the patients included in the Phase II/III study - 104 patients were analyzed out of a total of 156. Based on the safety and available efficacy data, the IDMC has recommended the continuation of the Phase II/III trial of NBTXR3 in soft tissue sarcoma.

"The IDMC's recommendation to continue the ongoing phase II/III trial of NBTXR3 is very positive news for soft tissue sarcoma patients, and an important milestone in NBTXR3's clinical development." said Elsa Borghi, Nanobiotix's Chief Medical Officer "Now, we look forward to seeing the full data analysis," she added.

The pivotal international Phase II/III study in soft tissue sarcoma was launched in Europe and Asia in October 2014 and aims to evaluate the safety and the efficacy of NBTXR3, a first in-class radio enhancer that could potentially target most solid tumors. The Phase II/III study is a prospective, randomized, multi-center, open label and active controlled two-armed study of 156 patients with locally advanced soft tissue sarcoma. The primary endpoint is the complete pathological response rate. The secondary endpoints are the objective response rate (ORR) by imaging (MRI); the evaluation of the safety profile in term of clinical and laboratory adverse events; the tumor volume changes; the resection margins and the limb amputation rate.

The IDMC is an international independent body of experts made up of scientists, statisticians and practicing physicians. Specifically, it was chartered to review and ensure: i) the data related to the primary endpoint, ii) the safety of all patients enrolled in the study, (iii) the quality of the data collected, and (iv) the continued scientific validity of the study design on two thirds of the patients treated.

The completion of recruitment for the Act.in.Sarc trial is planned by the end of Q2 2017. The full data analysis, except for long-term follow-up, is expected to be available at the end of 2017.

Based on the positive recommendation from the IDMC, the Company will communicate, over the coming weeks, its overall plan to move forward.

For more information about the study: Clinical trial.gov and http://www.actinsarc.com/.

About NANOBIOTIX: www.nanobiotix.com

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to providing a new, more efficient treatment for cancer patients.

NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.

NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases). Additionally, head and neck cancer and rectal cancer trials led by Nanobiotix's Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3.

The Company started in 2016 a new preclinical research program in Immuno-oncology with its lead product NBTXR3, which could have the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The Company Headquarters are based in Paris, France, with an affiliate in Cambridge, Massachusetts.

Contact

Nanobiotix
Sarah Gaubert
Director, Communications & Public Affairs
+33 (0)1 40 26 07 55
sarah.gaubert@nanobiotix.com / contact@nanobiotix.com

Noel Kurdi
Director, Investor Relations
+1 (646) 241-4400
noel.kurdi@nanobiotix.com / investors@nanobiotix.com

Media relations
France - Springbok Consultants
Marina Rosoff
+33 (0)6 71 58 00 34
marina@springbok.fr

United States - RooneyPartners
Marion Janic
+1 (212) 223-4017
mjanic@rooneyco.com

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the update of the reference document of Nanobiotix filed with the French Financial Markets Authority (Autorite des Marches Financiers) under number D.16-0732-A01 on December 27, 2016 (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country. At the moment NBTXR3 does not bear a CE mark and is not permitted to be placed on the market or put into service until NBTXR3 has obtained a CE mark.


Mar 24, 2017 07:00 HKT/SGT
Topic: Research and development
Sectors: Science & Research, BioTech, HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Nanobiotix
Sept 5, 2018 00:30 HKT/SGT
NANOBIOTIX half year results for the six months ended June 30, 2018
July 27, 2018 07:00 HKT/SGT
NANOBIOTIX signs a 40M EUR non-dilutive financing agreement with the European Investment Bank
June 22, 2018 09:00 HKT/SGT
NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3
June 6, 2018 22:00 HKT/SGT
NANOBIOTIX' Management Statement on Recent Share Price Variation
May 4, 2018 09:00 HKT/SGT
Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers
Apr 18, 2018 09:00 HKT/SGT
AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway
Apr 11, 2018 09:00 HKT/SGT
The University of Texas MD Anderson Cancer Center and Nanobiotix have an Agreement to Run Immunotherapeutic Pre-clinical Research in Lung Cancer Combining NBTXR3 and Nivolumab
Mar 30, 2018 22:10 HKT/SGT
Nanobiotix 2017 Annual Results
Jan 22, 2018 15:00 HKT/SGT
Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting
Jan 11, 2018 15:00 HKT/SGT
Nanobiotix Partners with Providence Cancer Institute to run Immunotherapeutic Preclinical Research in Pancreatic Cancers
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: